Cargando…
SOX8 Knockdown Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer by Inhibiting the Notch Signaling Pathway
Castration-resistant prostate cancer (CRPC) is still challenging to treat. Dissatisfaction with androgen signal-targeted therapy forces people to look for other treatment strategies. Therefore, this study is aimed at exploring the role of SOX8/Notch signaling in CRPC. The upregulation of SOX8, Notch...
Autores principales: | Du, Zhongbo, Chen, Xiaobin, Zhu, Pingyu, Sun, Wei, Lv, Qi, Cheng, Shulin, Yang, Xuesong, Yu, Xiaodong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560839/ https://www.ncbi.nlm.nih.gov/pubmed/36246971 http://dx.doi.org/10.1155/2022/9235837 |
Ejemplares similares
-
Systematic Evaluation for the Influences of the SOX17/Notch Receptor Family Members on Reversing Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells
por: Du, Zhongbo, et al.
Publicado: (2021) -
Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018) -
Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015) -
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015) -
Combination of phospholipase Cε knockdown with GANT61 sensitizes castration-resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway
por: Sun, Wei, et al.
Publicado: (2019)